13 Reddit Stocks with the Highest Upside Potential

6. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 60

Average Upside Potential: ~27.4%

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated that it delivered 18% sales growth in H1 2025. The company has lowered its full-year outlook because of lower growth expectations for its GLP-1 treatments in H2 2025. Therefore, it has been taking measures to sharpen its commercial execution further, and ensure efficiencies in its cost base while continuing to make investments in future growth. With over 1 billion people living with obesity globally, which includes over 100 million living in the US, and only a few million on treatment, Novo Nordisk A/S (NYSE:NVO) expects to maximise the strong growth opportunities, thanks to the healthy product portfolio and future pipeline.

Novo Nordisk A/S (NYSE:NVO) highlighted that the sales within Diabetes and Obesity care rose 16% in Danish kroner to DKK 145.4 billion (and 18% at CER), mainly due to the Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (and 58% at CER) and GLP-1 diabetes sales increasing 8% in Danish kroner (10% at CER). Within R&D, Novo Nordisk A/S (NYSE:NVO) plans to advance subcutaneous and oral amycretin into phase 3 development in weight management on the basis of completed clinical studies during Q1 2025. For FY 2025, the sales growth is anticipated to be 8% – 14% at CER, and operating profit growth is projected to be 10% – 16% at CER.

ClearBridge Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:

“We initiated a new position in Novo Nordisk A/S (NYSE:NVO), the global leader in diabetes care and one of two dominant players in the fast-growing GLP-1 diabetes and obesity drug market. A slowdown in prescriptions for Novo’s GLP-1 drugs, combined with confusion surrounding a clinical trial of its next-generation candidate, CagriSema, caused a significant pullback in the stock. We saw this as a buying opportunity. We believe the GLP-1 market remains vast and that Novo (alongside Eli Lilly) is well-positioned to maintain a duopolistic structure for years to come, given the complexity of manufacturing, differentiated intellectual property and brand strength. We also expect growth to reaccelerate as supply ramps up following its acquisition of Catalent and as regulators crack down on unlicensed compounders.”